The announcement of financial results can often lead to fluctuations in a company's stock price, depending on whether the results meet, exceed, or fall short of expectations. Additionally, the resubmission of the NDA for TransCon PTH indicates progress in Ascendis Pharma's product pipeline, which could be viewed positively by investors. However, the actual impact will depend on the details revealed during the conference call.